维甲酸协同砷剂治疗急性早幼粒细胞白血病的机制进展  

Mechanism of Retinoic acid combined with arsenic in the treatment of acute promyelocytic leukemia

作　　者：刘冯[1] 董敏[1] 肖丁华[1] LIU Feng;DONG Min;XIAO Dinghua(Department of Hematology,Affiliated Hospital,Guilin Medical University,Guangxi Zhuang Autonomous Region,Guilin541001,China)

机构地区：[1]桂林医学院附属医院血液科,广西桂林541001

出　　处：《中国医药导报》2020年第30期45-48,共4页China Medical Herald

基　　金：国家自然科学基金资助项目(81560032);桂林市科学研究与技术开发计划项目(2016012706-13);广西高校中青年教师基础能力提升项目(KY2016LX226)。

摘　　要：急性早幼粒细胞白血病(APL)是急性髓细胞白血病的一种特殊亚型。目前APL患者的首选治疗方案是维甲酸(RA)协同砷剂。近5年来,RA协同砷剂治疗APL的机制在分子生物学和细胞遗传学方面出现一些新的研究成果。本文主要从额外基因的改变、非基因的分子机制、联合药物的机制、佐剂和载体等进行阐述,从而为今后的基础研究提供参考。Acute promyelocytic leukemia(APL)is a special subtype of acute myeloid leukemia.The first-line treatment for APL patients is retinoic acid(RA)combined with arsenic at present.There has been some new research achievement about the mechanism of RA and arsenic in the treatment of APL appeared in molecular biology and cytogenetics in the past five years.This article mainly describes the changes of additional genes,non-genetic molecular mechanisms,mechanisms of combined drug,adjuvants and carriers,so as to provide a reference for future basic research.

关 键 词：急性早幼粒细胞白血病 维甲酸 砷剂 机制 

分 类 号：R733.7[医药卫生—肿瘤]